Biosimilars: An Emerging Therapeutic Approach

Abstract

A biosimilar is an extremely similar version of an existing medication. Biologics' cost, manufacture, administration, and clinical efficacy differ from those of chemically produced medications in certain aspects. Chemical and clinical equivalency to branded, original, low molecular weight chemical pharmaceuticals whose patents have expired defines generic medications. These are offered under a generic name and are practically the same thing as the original product. By 2020, many important biologics are expected to lose their patent protection, giving other biopharmaceutical companies the chance to create comparable biologics. After the first biosimilar was approved in early 2000, the use of biosimilars and similar biologics has expanded in recent years. One of the top producers of comparable biologics is India. In 2012, India created a new regulation for the pre- and post-marketing approval of comparable biologics. The biosimilar’s mode of action mirrors that of its reference drugs and results in very comparable outcomes. Some disorders, including some forms of cancer, can be treated with biologics and their biosimilars. Additionally, numerous medical disorders are treated with biosimilars. Crohn’s disease, arthritis, and ulcerative colitis.